This article is a correction to:
MXD3 as an Immunological and Prognostic Factor From Pancancer Analysis
Xiaoyu Zhang
Xiaoqin He
Yue Li
Yangtao Xu
Wenliang Chen
Xin Liu
Xinyao Hu
Lin Xiong2
Ximing Xu- 1Cancer Center, Renmin Hospital of Wuhan University, Wuhan, China
- 2Department of Pathology, Renmin Hospital of Wuhan University, Wuhan, China
Corrigendum on
MXD3 as an Immunological and Prognostic Factor From Pancancer Analysis
by Zhang, X., He, X., Li, Y., Xu, Y., Chen, W., Liu, X., Hu, X., Xiong, L., and Xu, X. (2021) Front. Mol. Biosci. 8:702206. doi: 10.3389/fmolb.2021.702206
In the published article, incorrect affiliation was included for Xiaoyu Zhang1, Xiaoqin He1, Yue Li1, Yangtao Xu1, Wenliang Chen1, Xin Liu1, Xinyao Hu1, Ximing Xu1. Instead of “1Wuhan University, Wuhan, China” it should be 1Cancer Center, Renmin Hospital of Wuhan University, Wuhan, China. In addition, incorrect affiliation was included for Lin Xiong2. Instead of “2Renmin Hospital of Wuhan University, Wuhan, China” it should be 2Department of Pathology, Renmin Hospital of Wuhan University, Wuhan, China.
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: MXD3, cancer, prognosis, methylation, immune, immune-infiltrating cell
Citation: Zhang X, He X, Li Y, Xu Y, Chen W, Liu X, Hu X, Xiong L and Xu X (2021) Corrigendum: MXD3 as an Immunological and Prognostic Factor From Pancancer Analysis. Front. Mol. Biosci. 8:826905. doi: 10.3389/fmolb.2021.826905
Received: 01 December 2021; Accepted: 02 December 2021;
Published: 22 December 2021.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2021 Zhang, He, Li, Xu, Chen, Liu, Hu, Xiong and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ximing Xu, doctorxu120@aliyun.com